Storm Warning: The Trial Disclosure Forecast for 2017
2017 will be a challenging year marked by public scrutiny of disclosure practices by regulators, stakeholders, and watchdog organizations. Expanded regulations require a significantly broader range of data to be disclosed within ever tighter timelines.
2016 saw renewed scrutiny of the transparency practices of industry and academic sponsors and the implementation of expanded disclosure regulations. 2017 is set to continue this trend as the new disclosure regulations become effective, inspections by regulatory agencies are likely to start, and new in-depth disclosure analyses and transparency indices are published. Enhanced transparency requirements will increase the effort to comply with regulations, while expectations for a broader scope of disclosure that exceeds regulatory requirements continue to grow.
To read the full article visit Pharmaceutical Processing.